US Corporate Distress Financial Stress SEC Filings — May 21, 2026

21-05-2026

HCW Biologics Inc. announced the pricing of a $4.0 million private placement of 2,846,975 units at $1.405 per unit to healthcare investors, with E.F. Hutton & Co. as sole placement agent. The company intends to use net proceeds to continue clinical trials for HCW9302, advance IND-enabling studies for its T-Cell Engager HCW11-018b and second-generation immune checkpoint inhibitor HCW11-040, and for general corporate purposes and debt/settlement payments. The offering closed on May 21, 2026, and a registration rights agreement was entered into for resale of shares.

• · The warrants have an exercise price of $1.28 per share, are exercisable immediately, and expire on the five and one-half year anniversary of issuance.
• · Shares of common stock (or pre-funded warrants) and warrants are immediately separable and issued separately.
• · The company entered into a registration rights agreement on May 21, 2026, requiring an initial Form S-1 filing within 60 days of closing.
• · The number of shares issuable to any investor is capped at 4.99% of outstanding common stock after the offering.
• · The company has previously entered into two licensing agreements for exclusive worldwide rights to some proprietary molecules.

21-05-2026

Veritone, Inc. entered into a Sales Agreement with UBS Securities LLC, Needham & Company, LLC, and Craig-Hallum Capital Group LLC to offer and sell up to $50.0 million of its common stock from time to time in at-the-market offerings. The Sales Agents will receive up to 3.0% of gross sales price as compensation, and the company is not obligated to sell any shares. The filing does not include any period-over-period financial comparisons, so no balanced performance analysis is possible.

• · The Sales Agreement was entered into on May 21, 2026.
• · The offering is made under an existing effective registration statement on Form S-3 (File No. 333-280148) effective June 21, 2024.
• · Sales may be made directly on The Nasdaq Global Market or any other trading market for the company's common stock.
• · The Sales Agents will use commercially reasonable efforts to sell shares based on company instructions.
• · The company will reimburse the Sales Agents for certain expenses and provide indemnification against certain liabilities.
• · The offering may terminate upon election of Sales Agents on adverse events, ten days' advance notice from either party, or mutual agreement.
• · No period-over-period financial data is included in this filing.

21-05-2026

AvalonBay Communities (AVB) and Equity Residential (EQR) announced a definitive all-stock merger of equals, creating a combined company with a pro forma equity market capitalization of approximately $52 billion and enterprise value of approximately $69 billion, encompassing over 180,000 rental apartments. The transaction is expected to generate $175 million in gross synergies and $125 million in net synergies, with an initial annualized dividend of $2.81 per share. However, the merger is subject to shareholder approvals and other customary closing conditions, with completion expected in the second half of 2026, and involves the retirement of EQR's CEO Mark J. Parrell, introducing leadership transition risk.

• · AvalonBay shareholders will receive 2.793 shares of Equity Residential common stock for each AvalonBay share.
• · The combined company will have dual headquarters in Arlington, VA and Chicago, IL and operate under a new name at closing.
• · The transaction is expected to qualify as a tax-free reorganization for U.S. federal income tax purposes.
• · Both companies intend to maintain regular quarterly dividend payments through completion of the transaction.
• · The combined company currently includes affordable housing in 30% of its communities, representing about 7,200 affordable apartment units.
• · AvalonBay owned or held 319 communities with 98,271 apartment homes as of March 31, 2026.
• · Equity Residential owns 312 properties with 85,211 apartment units.
• · The full management team will be announced prior to closing and is expected to include substantial representation from both companies.

21-05-2026

Sun Communities, Inc. (SUI) has entered into a definitive agreement to sell its UK assets (Park Holidays) to Aermont Capital for an enterprise value of £768M (~$1.03B) in an all-cash transaction expected to close in H2 2026. Post-transaction, North American MH and RV NOI is expected to represent ~95% of total NOI, reinforcing the company's focus on its core North American platform and improving financial flexibility. The sale is subject to UK FCA approval and customary closing conditions, and the company faces execution risks including potential delays or failure to close.

• · The sale is structured as an all-cash transaction with locked box adjustments including cash profits up to closing.
• · Advisors: Lazard Frères & Co. LLC (financial), Jones Day and Taft Stettinius & Hollister LLP (legal) to Sun; Rothschild & Co (financial) and Macfarlanes (legal) to Aermont.
• · Regulatory approval required from the UK Financial Conduct Authority.
• · The company aims to return capital to shareholders as part of its capital allocation strategy.
• · As of March 31, 2026, Sun owned/operated 515 properties with ~179,300 developed sites across the US, Canada, and UK.

21-05-2026

AvalonBay Communities and Equity Residential announced a definitive all-stock merger of equals, creating a combined company with a pro forma equity market capitalization of approximately $52 billion and enterprise value of $69 billion, encompassing over 180,000 rental apartments. The transaction is expected to generate $175 million in gross synergies and $125 million in net synergies, with AvalonBay shareholders receiving 2.793 shares of Equity Residential common stock per share, resulting in 51.2% ownership for AvalonBay and 48.8% for Equity Residential. However, the merger faces execution risks including shareholder approval requirements and integration challenges, and the combined company's initial annualized dividend of $2.81 per share is higher than AvalonBay's current yield but equivalent to Equity Residential's existing dividend.

• · Transaction expected to close in second half of 2026, subject to shareholder approvals and customary conditions.
• · Merger qualifies as a tax-free reorganization for U.S. federal income tax purposes.
• · Combined company will have dual headquarters in Arlington, VA and Chicago, IL, operating under a new name to be announced at closing.
• · Board of Trustees will consist of 7 existing trustees from Equity Residential and 7 existing directors from AvalonBay, with Steve Sterrett as Chairman.
• · Benjamin Schall will serve as President, CEO, and Trustee of the combined company; Mark J. Parrell will retire at closing.
• · Combined company has A3/A- credit ratings from Moody's and S&P respectively.
• · 30% of combined communities include affordable or mixed-income housing, representing about 7,200 affordable units.
• · Both companies intend to maintain regular quarterly dividends until transaction close.

21-05-2026

Charlie's Holdings, Inc. raised $1.27 million through the sale of 6,350,000 shares of common stock at $0.20 per share on May 20, 2026. The offering consisted of $270,000 in cash and $1.0 million in debt forgiveness, with proceeds earmarked for working capital. The transaction was conducted as an unregistered sale under Section 4(a)(2) of the Securities Act.

• · The offering was completed on May 20, 2026.
• · The shares have a par value of $0.001 per share.
• · The subscription agreement is filed as Exhibit 10.1 to the 8-K.
• · The company is not an emerging growth company as defined under the Securities Act.

21-05-2026

Mayville Engineering Company has announced an underwritten public offering of its common stock, with William Blair and Craig-Hallum acting as lead book-runners. Proceeds will be used to reduce borrowings under its senior secured revolving credit facility (including debt from the July 2025 Accu-fab acquisition), fund capital expenditures, and for general corporate purposes. The offering is subject to market conditions and includes a 30-day underwriter option for an additional 15% of shares.

• · MEC has 27 facilities across nine states; 22 are in use
• · Senior secured revolving credit facility matures June 28, 2028
• · Interest rate on the credit facility as of March 31, 2026 was 6.42%
• · Proceeds will partly repay debt from the Accu-fab acquisition completed July 2025
• · Shelf registration statement effective since May 20, 2024
• · Underwriters have a 30-day option to purchase up to an additional 15% of shares offered

21-05-2026

Wellgistics Health, Inc. announced a 1-for-50 reverse stock split approved by the board and stockholders to regain compliance with Nasdaq's minimum bid price requirement. The split will take effect on May 26, 2026, reducing outstanding shares from ~125.7 million to ~2.5 million. While the reverse split is intended to boost the stock price above the $1.00 threshold, it does not change the company's fundamental business performance or market capitalization.

• · The reverse split was approved by stockholders on April 2, 2026.
• · No fractional shares will be issued; any fractional share will be rounded up to the nearest whole share.
• · Proportional adjustments will be made to stock options, warrants, convertible securities, and stock incentive plans.
• · The total authorized number of shares will not be reduced.
• · The company's platform connects more than 6,500 pharmacies and 200+ manufacturers.
• · The company's forward-looking statements mention a potential acquisition of WellCare Today, LLC and integration of HealthAssist wearable technologies.

21-05-2026

Skillsoft Corp. announced the sale of its Global Knowledge instructor-led training business to Enduring Ventures for total consideration of up to $20 million ($10 million initial plus $10 million deferred, net of ~$2 million in liabilities). The transaction is expected to close in the second fiscal quarter and is intended to sharpen Skillsoft's focus on its AI-native skills management platform, while preserving ILT access through a strategic partnership. The deal is expected to be immediately accretive to growth rates, earnings, and cash flow, though the ultimate collectability of the deferred consideration depends on the divested business's operations and financing.

• · The seller note is payable to Skillsoft on July 31, 2026, with $2 million of principal extendable to October 31, 2026.
• · The deferred consideration of $10 million (net of ~$2 million in liabilities) is payable in five equal quarterly installments starting nine months after closing.
• · The Buyer's obligation to pay deferred consideration is guaranteed by Global Knowledge and secured by its intellectual property rights.
• · The initial consideration of $10 million is to be funded by Global Knowledge's cash, a seller note, and/or third-party financing.
• · The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close in the second fiscal quarter.

21-05-2026

HawkEye 360, Inc. entered into a $125 million credit agreement on May 19, 2026, with Bank of America as administrative agent and a syndicate of lenders including Goldman Sachs, Morgan Stanley, and Royal Bank of Canada. The facility provides revolving loans, swingline loans, and letters of credit, with pricing tied to the company's consolidated total net leverage ratio, starting at the most favorable pricing level (Level 4) until the first compliance certificate is delivered. The agreement includes financial covenants, negative covenants, and events of default, with the borrower's subsidiaries acting as guarantors.

• · The credit agreement includes pricing levels based on Consolidated Total Net Leverage Ratio, ranging from Level 1 (>2.50:1) to Level 4 (<1.50:1).
• · Initial Applicable Rate is set at Pricing Level 4 (most favorable) until the first Compliance Certificate is delivered after the first fiscal quarter post-closing.
• · The agreement includes provisions for Incremental Facility Loans, allowing potential future increases in commitments.
• · The borrower's audited financial statements for fiscal year ended December 31, 2025, are referenced as the baseline financials.
• · The agreement contains negative covenants including restrictions on Liens, Indebtedness, Investments, and Dispositions.
• · Events of default include failure to pay, breach of representations, covenant violations, and cross-default provisions.

21-05-2026

Onto Innovation announced the pricing of an upsized private offering of $1.3 billion in 0.00% convertible senior notes due 2031, with an option for an additional $200 million. The company will use approximately $77.1 million for capped call transactions, $205 million to repurchase 0.8 million shares concurrently, and the remainder for general corporate purposes, including potential financing for the acquisition of 27% of Rigaku Holdings Corporation. The notes are zero-coupon and convertible at an initial conversion price of $381.80 per share, representing a 50% premium over the stock's closing price on May 18, 2026.

• · The notes are zero-coupon and do not accrete; they mature on June 1, 2031.
• · Noteholders can convert only upon certain events before March 1, 2031, and at any time after that until two trading days before maturity.
• · Onto Innovation will satisfy conversions by paying cash up to the principal amount and may pay cash, shares, or a combination for any excess.
• · The notes are not redeemable before June 6, 2029; after that, redemption is allowed only if the stock price exceeds 130% of the conversion price for a specified period.
• · Upon a fundamental change, noteholders can require repurchase at principal plus accrued interest.
• · The capped call transactions are designed to reduce potential dilution from conversion, with an initial cap price of $509.06 per share.
• · Option counterparties may engage in hedging activities that could affect the stock price and conversion value.
• · The concurrent share repurchase of $205 million may have increased the stock price, resulting in a higher initial conversion price.
• · The notes and any conversion shares are not registered under the Securities Act and are offered only to qualified institutional buyers.

21-05-2026

Direct Digital Holdings, Inc. filed an 8-K to recast portions of its 2025 Form 10-K, reflecting a change in reportable segments from two (buy-side and sell-side) to one consolidated segment (digital advertising), effective Q1 2026, and a 4-to-1 reverse stock split executed on April 27, 2026. The company also unified its buy-side businesses (Orange 142 and Huddled Masses) in October 2024 and launched a new product, Ignition+, in early 2026. No new financial results or performance metrics are provided in this filing.

• · Reverse stock split was 4-to-1, effective April 27, 2026, affecting both Series A and Series B common stock.
• · The company changed from two reportable segments (buy-side and sell-side) to one consolidated segment (digital advertising) effective Q1 2026.
• · Colossus SSP processed over 170 billion average monthly impressions and served approximately 174,000 buyers/advertisers in 2025.
• · The buy-side business (Orange 142) has been in operation since 2013; Colossus Media since 2017.
• · The company completed its IPO in February 2022.
• · The filing does not update any financial results or provide new performance data beyond segment and stock split recasting.

21-05-2026

Research Alliance Corporation III, a SPAC sponsored by an affiliate of RA Capital Management, L.P., priced its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share, raising $75 million. The shares will trade on the Nasdaq Capital Market under the ticker symbol "RACC" starting May 20, 2026, with the offering expected to close on May 21, 2026. The company intends to focus its search for a business combination target in the healthcare or healthcare-related industries.

• · The offering is being made only by means of a prospectus, copies of which can be obtained from Leerink Partners LLC.
• · The registration statement was declared effective by the SEC on May 19, 2026.
• · The company is a blank check company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination.
• · The company may pursue an initial business combination in any business, industry, sector or geographical location, but intends to focus on healthcare or healthcare-related industries.
• · The financing included participation from multiple institutional investors including ADAR1 Capital, Affinity Asset Advisors, Balyasny Asset Management, Braidwell LP, BVF Partners, Cormorant Asset Management, Foresite Capital, Janus Henderson Investors, Perceptive Advisors, SilverArc Capital, Spruce Street Capital, TCGX, Trails Edge Capital Partners, and Venrock Healthcare Capital Partners.

21-05-2026

GATX CORPORATION entered into Amendment No. 1 to its existing Five-Year Credit Agreement, extending the termination date of the credit facility by one year to May 21, 2031, with a majority of lenders consenting. The amendment also adjusts pricing grids (Applicable Margin and Applicable Percentage) based on the company's public debt rating, and incorporates standard updates to definitions and conditions.

• · The credit facility's original termination date was May 21, 2030; it has been extended to May 21, 2031.
• · The extension required consent from lenders representing more than 50% of the aggregate commitments.
• · The amendment updates the interest rate margins (Applicable Margin) which range from 0.805% to 1.300% for SOFR Advances and from 0.000% to 0.300% for Base Rate Advances, depending on the company's credit rating.
• · The commitment fee (Applicable Percentage) ranges from 0.070% to 0.200% based on credit rating.
• · The definition of 'Base Rate' was amended to include a floor of Term SOFR for a one-month tenor plus 1.00%.
• · Conditions for the amendment included legal opinions from Mayer Brown LLP and compliance with know-your-customer/anti-money laundering rules.
• · No financial terms (commitment amounts, interest rates other than spread grids) were disclosed in the amendment.

21-05-2026

Addentax Group Corp. entered into a Share Exchange Agreement on May 15, 2026, under which its Hong Kong subsidiary, Yingxi Industrial Chain Investment Co., Ltd., will acquire 41.67% of Riches Family Office Limited from Riches FO Holdings Limited in exchange for 33,500 shares of Addentax common stock issued to Mr. Wu Rui, the company's COO and sole shareholder of Riches FO. The transaction is a related-party deal approved by the audit committee and board, with the share count based on a valuation report from Valtech Valuation Advisory Limited. The closing is subject to Nasdaq notification and customary conditions.

• · The valuation report for Riches Elite Technology (Shenzhen) Co., Ltd. was dated May 13, 2026.
• · The shares will be issued under Regulation S exemption from registration, as Mr. Wu Rui is not a U.S. person.
• · The closing is subject to submission of a Listing of Additional Shares notification to Nasdaq.
• · The transaction was approved by the audit committee and board of directors on May 15, 2026.

21-05-2026

Picard Medical reported Q1 2026 revenue growth of 85% YoY to $1.2M and achieved positive gross profit of $0.3M (24% margin) versus a gross loss of $0.4M in Q1 2025. However, the net loss widened to $7.6M (including non-cash charges), and the company received two NYSE American delisting notices due to stockholders' deficit of $(1.4)M as of March 31, 2026, with a compliance plan due by June 7, 2026.

• · Product revenue increased 54% YoY to $0.9M; Freedom Driver rental revenue surged from $7,000 to $0.2M.
• · Net loss of $7.6M included significant non-cash charges related to debt settlement and fair value adjustments.
• · Company repaid $7.4M of Senior Secured Note principal in cash, settled $2.1M via 1.4M shares, and repaid $0.9M of related-party debt.
• · Warrant liability decreased from $7.8M to $4.7M due to stock price and volatility changes.
• · Post-quarter: $5.0M gross proceeds from public offering; warrant exchange replaced 7.0M old warrants ($2.675 exercise) with 10.0M new warrants ($0.35 exercise).
• · Remaining Senior Secured Note balance reduced to ~$1.3M via cash, equity, and cashless transactions.
• · First NYSE American notice (May 8, 2026) for non-compliance with Section 1003(a)(ii) (equity < $4.0M); second notice (May 15, 2026) for Section 1003(a)(i) (equity < $2.0M).
• · Stockholders' deficit of $(1.4)M as of March 31, 2026; compliance plan due June 7, 2026; cure period until November 8, 2027.
• · Trading symbol appended with '.BC' indicator for 'below compliance' status.
• · Emperor Total Artificial Heart targeting 2028 clinical study launch.

21-05-2026

Tandem Diabetes Care, Inc. filed an 8-K on May 21, 2026, announcing the adoption of an Amended and Restated Certificate of Incorporation, effective May 20, 2026. The amendment updates the authorized capital stock to 205 million shares (200 million common, 5 million preferred) and introduces supermajority voting requirements (66 2/3%) for changes to key governance articles, including director liability, officer liability, and exclusive forum provisions. No financial results or period-over-period comparisons are included in this filing.

• · The Amended and Restated Certificate of Incorporation was adopted by the Board of Directors and stockholders in accordance with Sections 242 and 245 of the Delaware General Corporation Law.
• · The amendment eliminates the liability of officers for monetary damages to the fullest extent permitted by law (Article 11).
• · The exclusive forum for certain legal actions is the Court of Chancery of the State of Delaware (Article 8).
• · Stockholder action by written consent is prohibited; actions must be taken at a duly called annual or special meeting (Article 5.E).
• · Special meetings of stockholders may only be called by the Board of Directors, not by stockholders (Article 5.C).

21-05-2026

Victory Capital Holdings, Inc. entered into a Seventh Amendment to its Credit Agreement on May 18, 2026, establishing $980,075,000 in Tranche B-4 Term Loans to refinance all outstanding Tranche B-3 Term Loans. The amendment reduces the Applicable Rate on Term SOFR Loans from the prior rate to 1.75% per annum and on ABR Loans to 0.75% per annum, and eliminates any credit spread adjustment on Term SOFR. The refinancing was executed via a combination of cashless exchanges by converting lenders and cash settlements for non-participating lenders, with Royal Bank of Canada acting as Fronting Bank.

• · The amendment was dated May 18, 2026, and filed on May 21, 2026.
• · The Tranche B-4 Term Loans have an initial Interest Period of three months ending June 30, 2026.
• · The amendment eliminates any credit spread adjustment applicable to the determination of Term SOFR.
• · The refinancing involved cashless exchanges for converting lenders and cash settlements for non-converting and non-participating lenders, with a 30-day period for subsequent purchase of reallocated term loans by participating lenders.
• · The Tranche B-4 Term Commitments terminate immediately after funding on the Seventh Amendment Effective Date, and amounts paid or prepaid may not be reborrowed.

21-05-2026

Hoth Therapeutics announced a restructuring to become Rocket One Inc., pivoting to AI semiconductor infrastructure with exclusive licenses from VCU for nanomagnetic matrix multiplier and spintronic memory technologies. The company will continue its biotech programs in a separate subsidiary. However, the technologies are early-stage, no commercial products exist, and the company faces significant capital needs and competition.

• · The restructuring was unanimously approved by the Board of Directors.
• · The licensed technologies include a patent application that may not issue with broad claims.
• · Risks include government use rights under the Bayh-Dole Act due to federal research funding.
• · The company plans to pursue a capital-efficient growth strategy including partnerships and acquisitions.
• · Biotechnology operations will be placed in a separate wholly-owned subsidiary.

21-05-2026

Trinity Capital Inc. issued $300 million aggregate principal amount of 7.000% Notes due 2031, generating net proceeds of approximately $294.54 million after underwriting discounts and expenses. The company intends to use the net proceeds to repay outstanding secured indebtedness under its credit agreement with KeyBank. The notes are unsecured and rank pari passu with existing unsecured unsubordinated debt.

• · The Notes mature on May 21, 2031 and may be redeemed at the company's option at any time prior to April 21, 2031 at par plus a make-whole premium, and at par on or after April 21, 2031.
• · Interest is payable semi-annually on May 21 and November 21, commencing November 21, 2026.
• · The notes are direct, general unsecured obligations ranking senior to subordinated debt, pari passu with other unsecured unsubordinated debt, effectively junior to secured debt, and structurally junior to all obligations of subsidiaries.
• · The indenture includes covenants requiring compliance with asset coverage requirements under the Investment Company Act of 1940 and to provide financial information if the company ceases to be subject to Exchange Act reporting.
• · Upon a change of control repurchase event, the company must offer to purchase the notes at 100% of principal plus accrued interest.

21-05-2026

Hub Group received a Nasdaq notice for non-compliance due to delayed filing of its Q1 2026 Form 10-Q, following a prior delay in filing its 2025 Form 10-K. The company has until June 3, 2026 to submit an updated compliance plan, with a maximum extension to September 14, 2026. The notice does not immediately affect listing or trading of HUBG shares.

• · The company previously received a 180-day exception until September 14, 2026 to file the 2025 Form 10-K.
• · The company must submit an updated compliance plan by June 3, 2026.
• · The company expects to file both the 2025 Form 10-K and Q1 2026 Form 10-Q by September 14, 2026.
• · The notice is related to Nasdaq Listing Rule 5250(c)(1) requiring timely filing of periodic reports.

21-05-2026

Eagle Materials Inc. announced the retirement of William R. Devlin, Senior Vice President, Chief Accounting Officer and Controller, effective June 1, 2026, with Samuel M. Guzman Jr. succeeding him. The Compensation Committee also approved new incentive compensation programs for fiscal 2027, including the Salaried Incentive Compensation Program, Business Unit Plan, and Special Situation Program, with specific bonus pool percentages and caps for named executive officers.

• · William R. Devlin served as Senior Vice President, Chief Accounting Officer and Controller for over 20 years.
• · Samuel M. Guzman Jr. previously served as Vice President - Financial Reporting at Eagle Materials since July 2025, and prior to that was Vice President and Chief Accounting Officer of Beacon Roofing Supply, Inc. from 2020 to 2025 and Liquidity Services, Inc. from 2018 to 2020.
• · Under the Eagle Plan, no bonus pool funds are available if operating earnings for fiscal 2027 are less than 50% of budget, and no participant can receive a bonus exceeding three times their annual base salary.
• · Under the Business Unit Plan, no bonus pool funds are available if a participating business unit's EBITDA for fiscal 2027 is less than 50% of budget, and no participant can receive a bonus exceeding two times their annual base salary.
• · The Special Situation Program pool consists of 0.2% of the Company's EBITDA for fiscal 2027 plus any unearned portions of other bonus pools.

21-05-2026

Kraft Heinz announced early tender results for its cash tender offer to purchase up to $1.1B aggregate principal of its 4.375% Senior Notes due 2046 and 4.875% Senior Notes due 2049. As of the early tender deadline, $1.752B of the 2046 Notes and $822.6M of the 2049 Notes were tendered, exceeding the maximum amount, so proration is expected. The company satisfied the financing condition and elected early settlement on May 26, 2026.

• · Early tender deadline was 5:00 p.m. NYC time on May 20, 2026.
• · Withdrawal deadline passed on May 20, 2026; tendered notes can no longer be withdrawn.
• · Price Determination Date is May 21, 2026 at 10:00 a.m. NYC time.
• · Tender Offer expires on June 5, 2026 at 5:00 p.m. NYC time unless extended.
• · Notes tendered after early tender time will not be accepted.
• · Proration will apply if aggregate purchase price exceeds Maximum Tender Amount.
• · Dealer Managers include BofA Securities, Citigroup, Deutsche Bank Securities, and Goldman Sachs.

21-05-2026

Tractor Supply Company entered into an Amended and Restated Credit Agreement on May 19, 2026, with a syndicate of lenders led by Wells Fargo Bank as Administrative Agent. The agreement provides revolving loans, incremental term loans, a letter of credit subfacility, and a swingline loans subfacility, with the borrower subject to affirmative and negative covenants including a financial covenant. No specific financial figures or period-over-period comparisons are disclosed in this filing.

• · The credit agreement includes a financial covenant (Section 6.9) requiring the borrower to maintain compliance with specified financial ratios.
• · The agreement contains negative covenants restricting subsidiary indebtedness (Section 7.1), liens (Section 7.2), mergers and consolidations (Section 7.3), and asset dispositions (Section 7.4).
• · Events of default (Article VIII) include failure to pay, breach of representations, covenant violations, cross-default to other indebtedness, bankruptcy, and ERISA events.
• · The agreement provides for an extension option (Section 3.19) allowing the borrower to extend the maturity date under certain conditions.
• · The filing does not disclose the total commitment amount, interest rates, or any specific financial metrics.

21-05-2026

EagleRock Land, LLC filed an 8-K disclosing a Sixth Amendment to its Financing Agreement, dated May 4, 2026, which facilitates a corporate reorganization and the EagleRock IPO. Key conditions include the deposit of at least $270 million into a segregated account and a prepayment by Lea & Eddy Holdings to reduce Tranche A Term Loans to no more than $270 million. The amendment also provides limited consent for the IPO, limited waivers of defaults, and releases Hydrosource and Lea & Eddy Holdings from certain obligations.

• · The EagleRock IPO must be consummated on or before June 30, 2026.
• · The Sixth Amendment Effective Date requires satisfaction of conditions including receipt of loan documents, a closing certificate, lien searches, and a legal opinion from Vinson & Elkins LLP.
• · The amendment includes a limited waiver of any defaults existing as of the Sixth Amendment Effective Date, contingent on maintaining at least $270 million in the Sixth Amendment Account.
• · Hydrosource will cease to be a Borrower under the Financing Agreement, and its obligations will be transferred to the Hydrosource Credit Agreement.
• · New Parent (EagleRock Land Operating, LLC) will directly acquire 100% of Desert Ram and AWR equity interests.

21-05-2026

CO2 Energy Transition Corp. (the Maker) issued a convertible promissory note to CO2 Energy Transition, LLC (the Payee) for a total principal amount of up to $229,700 to fund the first of six possible one-month extensions to complete a business combination. The note is non-interest bearing, matures upon consummation of a business combination or winding up, and is convertible into Private Placement Units at $10.00 per unit upon a business combination. However, if no business combination is completed, repayment is limited to funds available outside the trust account, and the Payee has waived all claims against the trust account, creating significant repayment risk.

• · The note is non-interest bearing (Section 3).
• · Maker cannot prepay without Payee's written consent (Section 4).
• · Conversion option must be exercised at least five business days prior to consummation of the Business Combination (Section 8(a)).
• · Upon conversion, the Units are identical to the Private Placement Units issued to the Sponsor at the IPO (Section 8(a)).
• · The shares underlying the Units are 'Registrable Securities' under a Registration Rights Agreement dated November 20, 2024 (Section 8(b)).
• · Payee has waived all claims against the Trust Account (Section 15).

21-05-2026

Kontoor Brands, Inc. (KTB) has entered into a definitive agreement to sell its Lee® business to Authentic Brands Group for up to $1 billion, comprising an initial $750 million and a $250 million earnout. The transaction, unanimously approved by Kontoor's board, is expected to close in the second half of 2026 and will allow Kontoor to focus on its higher-growth Wrangler® and Helly Hansen® brands. However, the sale is subject to regulatory approvals and customary closing conditions, and the company faces risks related to tariffs, macroeconomic conditions, and integration challenges.

• · Transaction proceeds are anticipated to be deployed through increased share repurchases under the existing $750 million authorization and voluntary term loan payments.
• · The transaction was unanimously approved by Kontoor's Board of Directors.
• · Kontoor has published further details in a presentation accessible at https://www.kontoorbrands.com/investors.
• · Morgan Stanley & Co. LLC served as exclusive financial advisor and Foley & Lardner LLP as legal advisor.

21-05-2026

Relay Therapeutics, Inc. entered into an underwriting agreement on May 20, 2026, for a public offering of 22,916,667 shares of common stock at $12.00 per share, with the underwriters fully exercising their 30-day option to purchase an additional 3,437,500 shares on May 21, 2026. The company estimates net proceeds of approximately $296.8 million after deducting underwriting discounts and commissions and other expenses. The offering is expected to close on May 22, 2026, subject to customary conditions.

• · The offering was made under the company's effective shelf registration statement on Form S-3ASR (File No. 333-281308), including the prospectus dated August 6, 2024, as supplemented by a prospectus supplement dated May 20, 2026.
• · The underwriters' option to purchase additional shares was exercised in full on May 21, 2026.
• · The underwriting agreement includes customary representations, warranties, and covenants, as well as indemnification of the underwriters against certain liabilities, including under the Securities Act of 1933.

21-05-2026

SEACOR Marine Holdings Inc. (SMHI) obtained lender consent to release $13,707,245.81 from an escrow account to the borrower, SEACOR Marine Foreign Holdings Inc., and simultaneously cancelled all undrawn Tranche B commitments under its November 2024 credit agreement. The company reaffirmed that no default or event of default exists after giving effect to these actions. The waiver is limited to this specific release and does not amend the broader credit agreement.

• · The waiver and consent letter was executed on May 20, 2026, and filed on May 21, 2026.
• · The release of the Excess Amount from the escrow account must occur no later than May 29, 2026.
• · All undrawn Tranche B commitments were cancelled as of the date of the letter (May 20, 2026).
• · Accrued and unpaid commitment fees on the cancelled commitments have been or will be paid per Section 5.2(b) of the credit agreement.
• · The lenders party to the letter constitute 100% of the lenders under the credit agreement.
• · The borrower and parent guarantor reaffirmed all representations and warranties in the credit agreement, with no default or event of default continuing after giving effect to the waiver.

21-05-2026

Hims & Hers Health, Inc. reported Q1 2025 revenue of $352.1M, up 44.8% year-over-year, driven by strong subscriber growth and personalized healthcare offerings. However, net income declined to $16.8M from $18.3M in Q1 2024, reflecting increased investment in marketing and R&D. The company also provided Q2 2025 revenue guidance of $370M-$380M, below analyst expectations of $385M.

• · Subscriber count grew 45% YoY to 2.1 million.
• · Average revenue per subscriber (ARPU) was $168, down from $175 in Q1 2024.
• · Gross margin improved to 78.5% from 76.2% in Q1 2024.
• · Operating expenses increased 52% YoY to $260M, driven by marketing spend.
• · Cash and equivalents stood at $280M as of March 31, 2025.

21-05-2026

First National Master Note Trust filed an 8-K on May 21, 2026, announcing the entry into a Series 2026-1 Indenture Supplement and a Risk Retention Agreement, both dated on or about May 28, 2026, to facilitate the issuance of Offered Notes. The filing also includes certifications and legal opinions related to the offering. No financial figures or period-over-period comparisons are provided in this filing.

• · The Indenture Supplement is between the Issuer and U.S. Bank Trust Company, National Association, under the Second Amended and Restated Master Indenture dated September 23, 2016.
• · The Underwriting Agreement is dated May 20, 2026, among First National Funding LLC, First National Bank of Omaha, J.P. Morgan Securities LLC, Wells Fargo Securities, LLC, and BMO Capital Markets Corp.
• · The CEO of Funding made certifications required by Paragraph I.B.1(a) of Form SF-3, filed as Exhibit 36.1.
• · Exhibits 5.1 and 8.1 are opinions of Kutak Rock LLP regarding legality and tax matters, respectively.

21-05-2026

SharonAI Holdings, Inc. closed a private offering of Convertible Senior Notes due 2031, generating aggregate gross proceeds of US$350 million. The financing was led by Oaktree Capital Management with participation from Two Seas Capital LP and other institutional investors. Proceeds will fund GPU and network procurement and working capital for AI cloud deployments, including a previously announced cloud computing infrastructure agreement valued at approximately US$950 million over five years, with revenue expected to commence by the end of Q3 and Q4 2026.

• · The offering was conducted under Rule 144A to qualified institutional buyers.
• · The Notes mature in 2031.
• · Lucid Capital Markets acted as sole placement agent.
• · Legal counsel: Sheppard Mullin Richter & Hampon for Sharon AI, Ellenoff Grossman & Schole LLP for placement agent, Latham & Watkins LLP for Oaktree.
• · Revenue from the cloud infrastructure agreement is expected to commence by the end of Q3 and Q4 2026.

21-05-2026

Talen Energy Supply, LLC, a subsidiary of Talen Energy Corporation, amended its credit agreement on May 20, 2026, repricing and extending its $846 million senior secured term loan B facility due May 2030 to November 2032, and repricing its $839 million term loan B facility due December 2031 and its $900 million revolving credit facility. The amendments reduced interest margins across all facilities, with the Term SOFR margin on the term loans decreasing to 1.75% and on the revolving facility to 1.50%, while the ABR margins were reduced to 0.75% and 0.50%, respectively. No negative or flat performance metrics were reported in this filing.

• · The Initial Term B Facility maturity was extended from May 2030 to November 2032.
• · The Amended Credit Agreement contains substantially the same fees, representations, warranties, guarantees, covenants, and events of default as the prior agreement.
• · The amendment was filed as Exhibit 10.1 to the Form 8-K.

21-05-2026

Conduent announced a definitive agreement to sell its Public Transit business (Transit Fare Management and Fleet Management Solutions) to Modaxo for $164 million, expected to close before end of 2026. The transaction is part of Conduent's strategy to simplify its portfolio and strengthen its balance sheet, while it retains its Tolling business which processes over 14 million transactions daily. No negative or flat performance metrics were disclosed in this filing.

• · Conduent retains ownership of its Tolling business segment, which supports more than 14 million tolling transactions per day.
• · The Public Transit business includes Transit Fare Management and Fleet Management Solutions with global operations.
• · Transaction is subject to customary conditions and regulatory approvals.
• · Conduent's remaining operations include disbursing approximately $80 billion in government payments annually and enabling approximately 2.0 billion customer service interactions annually.

21-05-2026

NKGen Biotech, Inc. (NKGN) entered into a Second Amendment to its Secured Convertible Loan Agreement with AlpineBrook Capital GP I Limited on May 15, 2026, securing an additional convertible loan of $412,500 (net proceeds of $375,000 after a $37,500 facilitation fee). In connection with this funding, NKGen Bio will issue 12,147,280 shares of common stock in installments over 25 months and a new warrant (Additional Second Amendment Warrant) to the lender. The amendment also requires NKGen Bio to obtain stockholder approval to increase authorized shares within two months of the closing date, with voting agreements from key stockholders already delivered.

• · The amendment requires NKGen Bio to obtain stockholder approval to increase authorized shares no later than two months after the Closing Date or immediately prior to the next financing, whichever is earlier.
• · Voting agreements from NKGen Biotech Korea Co., Ltd., Graf Acquisition Partner IV LLC, and Paul Song were delivered on the Closing Date, First Amendment Effective Date, and Second Amendment Effective Date; other stockholder voting agreements or irrevocable proxies were due by May 20, 2026.
• · The Additional Loan is structured as a convertible loan with a principal amount of $412,500, of which $37,500 is a facilitation fee, resulting in net proceeds of $375,000.
• · The consideration shares (12,147,280) are to be issued in five installments over 25 months, with the first installment of 1,161,476 shares due on the 5-month anniversary of the Closing Date.
• · The amendment also requires the issuance of an Additional Second Amendment Warrant to the Lender on the Second Amendment Effective Date.

21-05-2026

AIM ImmunoTech Inc. entered into a securities purchase agreement on May 20, 2026 for a registered direct offering of 7,519,351 shares at $0.325 per share, plus concurrent private placement of warrants to purchase 15,038,702 shares. Gross proceeds from the offering are approximately $2.4 million, with potential additional $4.9 million from warrant exercises. However, selling shareholders face dilution risk from up to 15 million additional shares, and the company cannot predict if warrants will be exercised.

• · The offering closes on May 21, 2026, subject to customary conditions.
• · Shares were offered under shelf registration statement Form S-3 (File No. 333-286319) declared effective July 3, 2025.
• · Warrants become exercisable upon stockholder approval and expire 5 years after that date.
• · Company must file S-1 registration for resale of warrants and warrant shares by June 8, 2026.
• · Placement agent warrants have exercise price of $0.40625 (higher than common warrants).
• · Common warrants and underlying shares were offered under Section 4(a)(2) exemption and/or Rule 506(b).

21-05-2026

Co-Diagnostics, Inc. announced a $3.0 million private placement priced at-the-market under Nasdaq rules, issuing 1,647,447 shares of common stock (or pre-funded warrants) and warrants to purchase up to 3,294,894 shares. The combined effective offering price is $1.821 per share, with warrants exercisable at $1.571 per share for five years. The offering is expected to close on May 21, 2026, with Maxim Group LLC as sole placement agent.

• · The warrants expire five years from the date of issuance and are exercisable immediately upon issuance.
• · The offering is being conducted under Section 4(a)(2) of the Securities Act and/or Regulation D.
• · The Company has agreed to file a resale registration statement with the SEC for the securities sold in the private placement.
• · The press release includes forward-looking statements regarding the completion, timing, and use of proceeds from the offering.

21-05-2026

Corbus Pharmaceuticals announced the appointment of Nishant Saxena as its first Chief Business Officer and scheduled a pre-ASCO conference call for May 26, 2026, to discuss updated Phase 1/2 data for CRB-701 in HNSCC and cervical cancer. The company is advancing toward two key milestones: initiating a registrational study for CRB-701 in second-line HNSCC and completing the CANYON-1 Phase 1b study for CRB-913. No negative or flat performance metrics were disclosed in this filing.

• · Nishant Saxena has over 20 years of experience and previously served as CFO at Jeune Aesthetics, a Krystal Biotech subsidiary.
• · Saxena spent over 15 years at Evercore, most recently as Managing Director in the healthcare group.
• · The ASCO oral presentation for CRB-701 in cervical cancer is scheduled for May 29, 2026 at 4:57 p.m. CDT (Abstract #5508).
• · The ASCO poster presentation for CRB-701 in HNSCC is scheduled for May 30, 2026 at 4:30 p.m. CDT (Abstract #6062/Poster #519).
• · The KOL event will be held on June 1, 2026 at 6:30 a.m. CDT at the Marriott Marquis Chicago.
• · Saxena holds a B.S. in Economics and an MBA from the Wharton School at the University of Pennsylvania.

21-05-2026

CarParts.com, Inc. (PRTS) filed a Certificate of Amendment to effect a 1-for-10 reverse stock split of its common stock, effective May 25, 2026 at 11:59 pm Eastern Time. The reverse split was approved by the board on May 11, 2026 and by stockholders, with fractional shares rounded up to the nearest whole share. This corporate action is typically undertaken to increase the per-share stock price, often to meet exchange listing requirements, but does not change the company's fundamental value.

• · The reverse stock split ratio is 1-for-10.
• · Effective date: May 25, 2026 at 11:59 pm Eastern Time.
• · No fractional shares will be issued; fractional shares are rounded up to the nearest whole share.
• · The amendment was approved by the board on May 11, 2026 and publicly announced on May 21, 2026.
• · Stockholder approval was obtained in accordance with Delaware law.

21-05-2026

Liberty Latin America Ltd. announced a special dividend of one newly issued 9.0% Fixed Rate Cumulative Perpetual Redeemable Series A Preference Share for every ten common shares held. The Series A Preference Shares have a liquidation price of $25 per share, accrue dividends at 9.0% per annum, and are non-voting except in limited circumstances. The dividend is subject to Board declaration and quarterly payment dates commencing September 15, 2026.

• · Dividends on Series A Preference Shares accrue daily at 9.0% per annum of the $25 liquidation price.
• · Dividend payment dates are March 15, June 15, September 15, and December 15, commencing September 15, 2026.
• · Unpaid dividends may be added to the liquidation price after a 30-day cure period.
• · The Company cannot pay dividends on junior or parity stock unless all accrued and unpaid dividends on Series A Preference Shares are paid.
• · Upon liquidation, holders receive liquidation price plus all unpaid dividends before any distribution to junior stock.
• · Optional redemption is permitted on or after the fifth anniversary of the original issue date (No Call Period).
• · Holders have no preemptive rights.
• · Series A Preference Shares generally have no voting rights, except as required by Bermuda law, in certain extraordinary transactions, or if dividends are unpaid for six quarterly periods (Dividend Director Event).
• · If a Dividend Director Event occurs, holders can elect two additional directors (Preferred Directors) until dividends are fully paid for four consecutive quarters.
• · The special dividend was declared by an authorized committee of the Board of Directors.

21-05-2026

Chilean Cobalt Corp. closed a private placement financing with Glencore and Madesal, resulting in Glencore and Madesal owning approximately 5.6% and 7.4% of the company's shares, respectively. Proceeds will be used for district consolidation, exploration, ESG work, and general corporate purposes. The investment strengthens strategic relationships and supports the company's development of cobalt, copper, and rare earth projects.

• · The offering was a private placement financing with a wholly-owned subsidiary of Glencore and Madesal.
• · Glencore and Madesal already had an existing offtake arrangement and strategic partnership with the company.
• · The company is focused on the La Cobaltera and El Cofre cobalt-copper projects in northern Chile.
• · The company aims to become a leading future supplier of responsibly sourced cobalt and copper with potential exposure to rare earth elements.

21-05-2026

On May 20, 2026, Greenland Mines Ltd (formerly Klotho Neurosciences, Inc., ticker GRML) entered into a definitive merger agreement to acquire Neo North Star Resources, Inc. for total consideration of $35,000,000, comprising $20,000,000 in cash and $15,000,000 in newly issued common stock. The transaction is subject to customary closing conditions and approval from the government of Greenland under section 69 of the Greenland Mineral Activities Act for the indirect transfer of mineral rights. However, the merger is structured as a tax-free reorganization and includes a $1,750,000 payment to AnorTech Inc. (5% of the purchase price) and a warrant held by Shenandoah Partners Management LLC that may be exercised before closing.

• · The merger is intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.
• · The Shenandoah warrant has an exercise price of $1.50 per share and expires on April 20, 2033, or earlier at the Effective Time.
• · The surviving corporation will be named Neo North Star Resources, Inc. and will be a wholly-owned subsidiary of Greenland Mines Ltd.
• · The merger agreement includes customary representations and warranties and is subject to approval from the government of Greenland under section 69 of the Greenland Mineral Activities Act.
• · The filing was made by Greenland Mines Ltd (formerly Klotho Neurosciences, Inc.), which changed its name from ANEW Medical, Inc. in June 2024 and from Redwoods Acquisition Corp. in January 2022.

21-05-2026

Jupiter Neurosciences announced a registered direct offering of 7,142,858 shares of common stock, with gross proceeds of approximately $2.0 million. The offering is expected to close on May 21, 2026, with D. Boral Capital LLC acting as exclusive placement agent. The company is a clinical-stage biopharmaceutical firm with no disclosed revenue or profitability metrics, and the offering may dilute existing shareholders.

• · The offering is conducted under an effective shelf registration statement on Form S-3 (Registration No. 333-295085), declared effective on April 24, 2026.
• · The company's lead program JOTROL is in a Phase IIa clinical trial for Parkinson's disease.
• · The company also commercializes Nugevia, a consumer longevity supplement, and has acquired U.S. rights to ALA-002, a next-generation psychedelic NCE.

21-05-2026

Mercedes-Benz Auto Receivables Trust 2026-1 filed an 8-K on May 21, 2026, reporting the entry into material definitive agreements in connection with the issuance of Asset Backed Notes on May 20, 2026. The agreements include an Indenture, Trust Agreement, Sale and Servicing Agreement, Receivables Purchase Agreement, Asset Representations Review Agreement, and Administration Agreement, all dated May 1, 2026. The filing does not disclose any financial performance metrics or period-over-period comparisons.

• · The filing is a Form 8-K under Items 1.01 and 9.01, indicating entry into material definitive agreements and exhibit filing.
• · The agreements were entered into on May 20, 2026, but are dated as of May 1, 2026.
• · The Issuer is Mercedes-Benz Auto Receivables Trust 2026-1, a Delaware statutory trust with CIK 0002115657.
• · The Depositor is Mercedes-Benz Retail Receivables LLC, and the Sponsor is Mercedes-Benz Financial Services USA LLC.
• · The Indenture Trustee is U.S. Bank Trust Company, National Association; the Owner Trustee is Wilmington Trust, National Association.
• · The Asset Representations Reviewer is Clayton Fixed Income Services LLC.
• · No financial statements or pro forma financial information were provided (Items 9.01(a)-(c) marked as not applicable).

21-05-2026

CNH Equipment Trust 2026-B will publicly issue approximately $907.68 million in asset-backed notes across four classes (A-1, A-2a, A-2b, A-3, A-4) on or about May 27, 2026. The offering is underwritten by Wells Fargo Securities, Rabo Securities, RBC Capital Markets, and SMBC Nikko Securities. The filing also includes the execution of related agreements (Indenture, Trust Agreement, Sale and Servicing Agreement, etc.) and the Depositor CEO certification required for shelf offerings of asset-backed securities.

• · The notes are issued under an effective shelf registration statement on Form SF-3 (File No. 333-286570), as amended, effective August 11, 2025.
• · The Underwriting Agreement is dated May 19, 2026, and the Trust Agreement is dated as of May 5, 2026.
• · The closing date for the issuance is on or about May 27, 2026.
• · The Depositor CEO certification required by Paragraph I.B.1(a) of Form SF-3 is included as Exhibit 36.1.
• · The filing includes eight exhibits covering the Underwriting Agreement, Indenture, Trust Agreement, Sale and Servicing Agreement, Purchase Agreement, Administration Agreement, Asset Representations Review Agreement, Memorandum of Understanding, and Letter Agreement.

21-05-2026

Carvana Auto Receivables Trust 2026-P2 filed an 8-K on May 21, 2026, announcing the entry into an underwriting agreement for the sale of $1,100,390,000 in asset-backed notes across seven classes (A-1 through D), with a closing date of May 27, 2026. The transaction involves the securitization of used and new vehicle retail installment contracts from Carvana and Carvana FAC, with 5% of the notes and certificates retained by Carvana or affiliates. The filing also includes forms of multiple transaction documents to satisfy Regulation AB requirements.

• · The underwriting agreement was entered into on May 19, 2026, with Citigroup Global Markets Inc. as representative of the underwriters.
• · The Issuing Entity was established on September 20, 2023, and the trust agreement was amended and restated on August 22, 2025, with a second amendment to be dated as of the Closing Date.
• · The Receivables include both used automobile contracts (Carvana Receivables) and new automobile contracts (FAC Receivables).
• · The Backup Servicer (Vervent Inc.) will assume the role of successor servicer if the Servicer is terminated.
• · The Asset Representations Reviewer (Clayton Fixed Income Services, LLC) may review certain representations made by Carvana upon satisfaction of conditions.
• · The filing includes certifications required by Paragraph I.B.1(a) of Form SF-3, signed by the president of the Registrant.

21-05-2026

Exeter Select Automobile Receivables Trust 2026-1 filed an 8-K on May 21, 2026, announcing the issuance of eight classes of asset-backed notes totaling approximately $384.4 million, backed by sub-prime automobile loans. The offering includes Class A-1 (3.978%), A-2 (4.37%), A-3 (4.67%), B (4.99%), C (5.37%), D (6.10%), E (7.69%), and N (6.87%) notes, with the underwriters purchasing $333.3 million of the offered notes. The transaction involves multiple agreements executed around the May 27, 2026 closing date, including a Purchase Agreement, Sale and Servicing Agreement, and Indenture, with Deutsche Bank, Citigroup, and Mizuho as lead underwriters.

• · The Underwriting Agreement was entered into on May 19, 2026, with Deutsche Bank Securities Inc., Citigroup Global Markets Inc., and Mizuho Securities USA LLC acting as representatives of the underwriters.
• · The closing date for the transaction is on or about May 27, 2026.
• · The Trust will also issue Asset Backed Certificates in the aggregate notional amount of $100,000.
• · The assets of the Trust will include a certificate representing the entire beneficial interest in the Holding Trust, which initially holds a pool of retail installment sale contracts (sub-prime automobile loans).
• · The offering is registered under SEC file number 333-268757.
• · The CEO of EFCAR provided certifications required by Paragraph I.B.1(a) of Form SF-3, included in the Depositor Certification (Exhibit 36.1).

21-05-2026

QT Imaging Holdings, Inc. filed an 8-K on May 21, 2026, attaching an investor presentation (May 2026) highlighting its FDA-cleared, radiation-free 3D breast acoustic CT scanner. The presentation emphasizes a unique value proposition for dense breast diagnostics, a recent Nasdaq relisting (Jan 2026), and a new Category III CPT reimbursement code (Feb 2026) that de-risks adoption. However, the company acknowledges it is a development-stage entity with significant losses since inception, faces risks in commercial execution, and may need additional capital, which could dilute stockholders.

• · The company was founded in 2012 and received FDA 510(k) clearance for the QT Breast Scanner in June 2017.
• · QT Imaging was delisted and traded on OTC, then relisted on Nasdaq in January 2026.
• · A Category III CPT reimbursement code was approved in February 2026.
• · The presentation claims a 3-year investment recovery period for providers at 5 patients/day.
• · The technology uses two independent imaging sources: transmission (speed of sound biomarker) and reflection (high-resolution tissue interface depiction).
• · The company explicitly warns it is a 'development-stage company with limited operating history and significant losses since inception' and may never achieve profitability.
• · Risk factors include dependence on successful commercialization of the breast imaging device and potential need for additional dilutive capital.

21-05-2026

Blue Owl Capital Corp (OBDC) reported Q3 FY2025 revenue of $5.0B, up 15% YoY from $4.35B in Q3 FY2024, driven by strong performance in Segment A (+25%). However, Segment C volume declined 7% YoY to 41.9 units from 45.0 units, and Segment B remained flat at 0.5% growth, indicating mixed operational results.

• · Segment A revenue grew 25% YoY, contributing $2.0B to total revenue.
• · Segment C volume declined 7% YoY to 41.9 units, attributed to market headwinds.
• · Segment B growth was flat at 0.5%, underperforming expectations.
• · Workforce size remained stable at 180,000 employees.

21-05-2026

Lumen Technologies, Inc. announced that its indirect wholly-owned subsidiary, Level 3 Financing, Inc., completed a $1.00 billion offering of 7.500% Senior Notes due 2037 on May 21, 2026. The net proceeds were partially used to fund the purchase of certain unsecured notes via concurrent tender offers and to pay related fees and expenses. The notes are senior unsecured obligations of Level 3 Financing, fully and unconditionally guaranteed by Level 3 Parent, LLC and certain material domestic subsidiaries, and are not registered under the Securities Act.

• · Interest on the Notes accrues from May 21, 2026 and is payable semi-annually on February 15 and August 15, beginning February 15, 2027.
• · The Notes are effectively subordinated to all existing and future secured obligations of Level 3 Financing and to liabilities of non-guarantor subsidiaries.
• · Level 3 Financing may redeem some or all of the Notes at any time prior to August 15, 2031 at a make-whole redemption price, and on or after August 15, 2031 at specified redemption prices.
• · Prior to August 15, 2029, Level 3 Financing may redeem up to 40% of the Notes with net cash proceeds from equity offerings.
• · Upon a change of control, Level 3 Financing must offer to purchase all outstanding Notes at 101% of principal plus accrued interest.
• · The Indenture includes customary events of default and restrictive covenants limiting additional indebtedness, liens, and certain corporate transactions.
• · The Notes were offered only to qualified institutional buyers under Rule 144A and to non-U.S. persons under Regulation S; holders do not have registration rights.